were conducted with active participation of industry and public researchers in major cities. Interactions with industry bodies, the global research community, and national policy planners further enhance the awareness of BIPP.

Table 4 depicts the total proposals received and approvals granted for each call for BIPP proposals, across biotechnology application areas. In the two and a half years since BIPP‘s inception in December 2008 to end-July 2011, 16 batches of applications have been processed, 474 projects have been evaluated, and 61 proposals have been funded. Of these 16 calls for proposals, 9 have been general calls and 7 have been special calls: H1N1 vaccine development (call number 4), bio-similars (officially-approved subsequent versions of more complex molecular biopharmaceutical products following patent expiry on the original product, call number 8), affordable healthcare products (no.9), anti-virals (no.10), priority agriculture areas (no.11), value addition to agricultural produce for food and non-food applications (no.14), and affordable healthcare technologies (no.16). Over the first 11 batches, an average of 16% of applicants has secured funding (60 out of 368 applicants). The success ratio has varied between a low of 4% (1 out of 26 applicants in the December 1, 2010 special call for affordable healthcare technologies) and a high of 24% (6 out of 25 applicants in the September 2010 special call for bio-similars).

**Table 4: BIPP applications and approvals (as of August 1, 2011)**

|**CALLS**|**1**|**2**|**3**|**4***|**5**|**6**|**7**|**8***|**9***|**10 ***|**11 ***|**12**|**13**|**14***|**15**|**16***|**Total**|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|**Closing Date**|Dec08|June09|Aug09|Aug09|Dec09|Apr10|July10|Sept10|Dec10|Dec10|Dec10|Dec10|Mar11|Mar11|Aug11|Aug11||
|**Health-care**|34|3|22|5|20|9|11|10|6|21|0|8|9|0|4|9|**171**|
|**Agriculture**|6|5|4|0|11|6|6|0|1|0|26|0|11|11|5|0|**92**|
|**Clinical Trial**|13|1|11|1|13|3|3|3|3|2|0|3|4|0|3|2|**65**|
|**Ind. products**<br>**&processes**|2|1|6|1|7|1|3|8|6|0|0|0|3|7|0|0|**45**|
|**Bio-medical**<br>**devices and**<br>**instruments**|2|1|0|0|2|0|2|0|1|7|0|0|2|0|3|16|**36**|
|**Infrastructure**|0|12|7|3|1|0|2|4|3|0|0|0|0|0|2|0|**34**|
|**Bio-energy**|5|1|6|0|1|0|1|0|2|0|0|0|1|0|2|0|**19**|
|**Field Trial**|2|0|1|0|0|2|1|0|0|0|1|0|0|0|0|0|**7**|
|**Environmental**<br>**Biotechnology**|0|0|0|0|0|0|0|0|4|0|0|0|0|0|1|0|**5**|
|**Total:**|**64**|**24**|**57**|**10**|**55**|**21**|**29**|**25**|**26**|**30**|**27**|**11**|**30**|**18**|**20**|**27**|**474**|
|**Supported**<br>**Projects**|**10**|**4**|**11**|**2**|**7**|**4**|**6**|**6**|**1**|**5**|**4**|**1**|**0**|**0**|**0**|**0**|**61**|
|**RATIO**|15.6%|16.7%|19.3%|20.0%|12.7%|19.0%|20.7%|24.0%|3.8%|16.7%|14.8%|9.1%|0%|0%|0%|0%|12.9%|

Source: DBT BIPP database; asterisks denote special calls (see text for details).

To mid-2011, BIPP has deployed $36 million, of which $13 million in grants and $23 million in soft loans, with a debt-to-grant ratio of roughly 2 to 1. Public BIPP funding has leveraged an additional $66 million in private investment by the recipient enterprises in the approved 61 projects as their core contribution, for a total investment of $102 million across approved projects. It is noteworthy that under a shorter span of time (two-and-a-half years versus fiveand-a-half years for SBIRI), BIPP has leveraged roughly the same amount of public funding ($36 million) into twice as much additional private sector contributions ($66 million versus $33 million additional private investment under SBIRI).

30